Robert Lee Johnson

Robert Lee Johnson

Auto-generated profile, based on publicly available information

Robert Lee Johnson

Eli Lilly and Company, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
FWFa Wang
Fa Wang
RJRobert L. Johnson
Robert L. Johnson
PSPaul W. Snyder
Paul W. Snyder
MDMarsha L. DeSmet
Marsha L. DeSmet
JFJames C Fleet
James C Fleet
Background Animal models are an important tool to understand intestinal biology. Our laboratory previously generated C57BL/6-Tg(Car1-cre)5Flt transgenic mice (CAC) with large-intestine-specific Cre recombinase (Cre) expression as a model to study colon health. Aim To expand the utility of the CAC mouse model by determining the impact of chemically induced colitis on CAC transgene expression. Methods CAC mice were crossed to Rosa reporter mice (Rosa26R flox/flox) with a lox-STOP-lox signal controlling β-galactosidase (βgal) expression and then further crossed with ApcCKO/CKO mice in some experiments to delete Apc alleles (ApcΔ580). Initially, 8-week-old CACTg/WT;Rosa26R flox/WT ;Apc Δ580/WT mice were treated with dextran sulfate sodium (DSS) in drinking water (5 days, 0, 0.65, 1.35, or 2.0 %). Colon tissue damage and βgal labeling were analyzed 10 day after stopping DSS. Next, 8-week-old CACTg/WT;Rosa26Rflox/flox mice were treated with 0 or 1.35 % DSS, and colonic βgal labeling was assessed at 30 day post-DSS treatment. Finally, 10-week-old CACTg/WT;Apc Δ580/WT mice were treated with DSS (0 or 2 %) for 5 days and colonic tumors were analyzed at 20 weeks. Results CACTg/WT;Rosa26R flox/WT ;Apc Δ580/WT mice had a DSS dose-dependent increase in colon epithelial damage that correlated with increased epithelial βgal labeling at 10 days (r 2 = 0.9, β = 0.75). The βgal labeling in CACTg/WT;Rosa26Rflox/flox mice colon remained high at 30 days, especially in the crypts of the healed ulcer. DSS also increased colon tumor incidence and multiplicity in CACTg/WT;Apc Δ580/WT mice. Conclusions DSS-mediated epithelial damage induces a persistent, Cre-mediated recombination of floxed alleles in CAC mice. This enables the examination of gene function in colon epithelium during experimental colitis and colitis-induced colon cancer.

1 April 2015 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
MDMarsha DeWitt
Marsha DeWitt
RJRobert L. Johnson
Robert L. Johnson
PSPaul Snyder
Paul Snyder
JFJames C Fleet
James C Fleet

29 January 2025 in Toxicologic Pathology
Verified
Journal Article
Closed access
MGMagali R. Guffroy
Magali R. Guffroy
TATara Arndt
Tara Arndt
EBErio Barale-Thomas
Erio Barale-Thomas
SBSusan Bolin
Susan Bolin
AGArmelle Grevot
Armelle Grevot
RJRobert L. Johnson
Robert L. Johnson
Nonhuman primates (NHPs) have been and remain a highly valuable animal model with an essential role in translational research and pharmaceutical drug development. Based on current regulatory guidelines, the nonclinical safety of novel therapeutics should be evaluated in relevant nonclinical species, which commonly includes NHPs for biotherapeutics. Given the practical and ethical limitations on availability and/or use of NHPs and in line with the widely accepted guiding “3Rs” (replace, reduce, and refine) principles, many approaches have been considered to optimize toxicity study designs to meaningfully reduce the number of NHPs used. Standard general toxicity studies usually include four groups of equal size, including one group of vehicle control animals. Here, we describe an approach to achieve an overall significant reduction in control animal use, while also resolving many of the issues that may limit application of fully virtual control animals. We propose in Good Laboratory Practice (GLP)-compliant toxicity studies to maintain concurrent control group animals for the in-life phase of the studies, but to limit euthanasia to a subset of control animals. The nonterminated control animals can then be returned to the facility colony for reuse in subsequent studies. The proposed study design could lead to a 15% to 20% reduction in NHP usage. The scientific, logistical, and animal welfare considerations associated with such an approach and suggested solutions are discussed in detail.

1 January 1993 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
DPD K Patel
D K Patel
RLR P Lewis
R P Lewis
MHM L Hinton
M L Hinton
DSD H Schroeder
D H Schroeder
JSJ P Shockcor
J P Shockcor
CSC W Sigel
C W Sigel


23 July 2026 in Blood Cancer Discovery
Verified
Journal Article
Closed access
NBNathan A. Brooks
Nathan A. Brooks
ASAnna Skwarska
Anna Skwarska
VSVivian Salama
Vivian Salama
MBMark H. Bender
Mark H. Bender
LKLisa Kays
Lisa Kays
RGRaymond Gilmour
Raymond Gilmour
Acute myeloid leukemia (AML) is an aggressive blood disorder characterized by rapid growth of poorly differentiated myeloid cells. Gain-of-function mutations in isocitrate dehydrogenases (IDH) are detected in ∼20% of AML and ∼80% of secondary gliomas. Mutant IDH1/2 isoenzymes acquire neomorphic activity to produce 2-hydroxyglutarate (2-HG) oncometabolite, resulting in hypermethylated DNA and histones, altered gene expression, and blocked differentiation of hematopoietic progenitors. Here, we present preclinical development of LY3410738, an oral, dual IDH1/2 inhibitor with potential to penetrate the blood–brain barrier. LY3410738 covalently inhibited mutated IDH1/2, reduced 2-HG levels at low nanomolar concentrations in human AML and glioma models, and demonstrated efficacy in AML patient-derived xenografts (PDX) in vivo, inducing myeloid differentiation. LY3410738 retained in vitro activity in cancer models with acquired secondary IDH1/2 mutations conferring resistance to ivosidenib and enasidenib. LY3410738 synergized and was well tolerated with standard-of-care regimens such as cytarabine, azacitidine, venetoclax, or midostaurin in IDH1/2-mutated AML PDXs. Significance: LY3410738 represents a promising advancement in the treatment of IDH1/2-mutated AML. Its irreversible binding and targeting of both IDH1/2 isoforms, coupled with sustained activity against mIDH1/2 with acquired second-site resistance mutations, distinguishes LY3410738 from clinically available IDH inhibitors and suggests therapeutic potential for patients with AML resistant to standard IDH-based treatment.